Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: A clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer, primarily focusing on the galectin-3 inhibitor belapectin. The company has no product revenue and operates at a loss.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,046) | $(9,631) |
| Net Loss per Share (Basic/Diluted) | $(0.08) | $(0.15) |
| Operating Expenses | $4,077 | $7,897 |
| Cash and Cash Equivalents (End of Period) | $14,111 | $7,431 |
| Net Cash Used in Operating Activities | $(3,866) | $(7,689) |
| Total Liabilities | $145,996 | $145,727 |
| Stockholders' Deficit | $(131,960) | $(127,918) |
Debt Structure: Significant related-party debt exists, including convertible notes payable ($32.9M) and borrowings under a convertible line of credit ($102.8M), all maturing June 30, 2027. Derivative liabilities related to contingent interest on these notes totaled $2.98M.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 47.6% to $5.0M, driven primarily by a $4.3M reduction in Research and Development (R&D) expenses.
- R&D Expense Decline: R&D expenses dropped from $6.5M to $2.2M. This decrease is attributed to the completion of the NAVIGATE clinical trial in Q1 2025 and reduced pre-clinical activity.
- Increased G&A Expenses: General and Administrative expenses rose 30.7% to $1.8M, largely due to a $302k increase in non-cash stock-based compensation.
- Derivative Liability Gain: The company recorded a $983k gain from the change in fair value of derivative liabilities, compared to a $25k loss in the prior year, reducing the overall net loss.
- Cash Position: Cash balances increased to $14.1M from $7.4M year-over-year, despite a net cash burn of $3.9M for the quarter.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($14.1M) plus $10M available under a related-party line of credit is sufficient to fund operations through May 2027. Additional capital will be required thereafter.
- Clinical Progress: Top-line results for the NAVIGATE trial (prevention of esophageal varices in MASH cirrhosis) were presented in December 2024. While the primary composite endpoint did not reach statistical significance in the intent-to-treat population, the per-protocol population showed a 49.3% reduction in varices incidence (p<0.05). A Type C meeting with the FDA is scheduled for Q2 2026.
- Internal Control Weakness: The company disclosed a material weakness in internal controls over financial reporting related to the valuation of derivative liabilities associated with convertible notes. Remediation efforts are ongoing.
- Risk Factors: Key risks include dependence on Chairman Richard Uihlein for financing, the early stage of development, and the uncertainty of future capital raises. The company has no plans or funding for a new clinical trial beyond the current analysis of NAVIGATE data.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $10M related-party line of credit and the terms of the extension to June 2027.
- Debt Conversion Risk: Assess the potential dilution from the conversion of ~$135M in related-party debt and notes, which have conversion prices ranging from $3.00 to $5.43.
- Internal Controls: Monitor the remediation plan for the material weakness regarding derivative liability valuation.
- Regulatory Path: Track the outcome of the FDA Type C meeting in Q2 2026 regarding the NAVIGATE trial data and potential next steps for belapectin.
- Stock-Based Compensation: Review the impact of recent stock option grants (1.02M options granted in Q1 2026) on future expense recognition.